Macular Hole

Evidence-based assessment and management of full-thickness foveal defects. Comprehensive clinical guide covering etiology, Gass and IVTS classification, OCT-based diagnosis, vitreoretinal surgical options, and optometry co-management protocols.

Last updated: March 2026

Figure 1. Publication-style cross-sectional schematic of a full-thickness macular hole (Gass Stage 3–4 / IVTS “large”). The full-thickness defect (A) extends through all neurosensory retinal layers from the internal limiting membrane to the retinal pigment epithelium. Elevated, oedematous hole edges (B) with intraretinal cystoid spaces (G) and reactive gliosis are characteristic. A free-floating operculum (C) composed of avulsed ILM and Müller cell remnants is visible in the vitreous cavity following posterior vitreous detachment (D). A cuff of subretinal fluid (E) surrounds the hole margins. The RPE at the hole base (F) is exposed, with yellow deposits representing xanthophyll pigment, lipid-laden macrophages, and degenerative debris. The ILM (H) shows characteristic curling at the hole edges. Layer labels (right) correspond to standard OCT nomenclature. Minimum linear diameter (MLD) measurement at the narrowest hole aperture is the primary metric for IVTS classification.

Gass Classification — Staging Progression

Figure 2. Gass staging progression of idiopathic macular hole, from Stage 1a (impending — foveal yellow spot with pseudocyst) through Stage 4 (full-thickness hole with complete PVD and Weiss ring). Approximate visual acuity ranges shown for each stage.

A macular hole is a full-thickness defect of the neurosensory retina centred at the fovea, resulting in disruption of all retinal layers from the internal limiting membrane (ILM) to the retinal pigment epithelium (RPE). The condition predominantly affects women over 60 years of age and is typically unilateral, though bilateral involvement occurs in approximately 10–15% of idiopathic cases. The estimated prevalence is 3.3 per 1,000 individuals aged over 55 years.

The hallmark presentation includes central scotoma, reduced visual acuity, and metamorphopsia. Without surgical intervention, spontaneous closure is uncommon in full-thickness holes; pars plana vitrectomy (PPV) with ILM peeling and gas tamponade achieves anatomical closure in over 90% of cases, with meaningful visual recovery in the majority of patients. Optical coherence tomography (OCT) has transformed both diagnosis and surgical planning, replacing the Gass biomicroscopic staging system with quantitative anatomical metrics.

Idiopathic (Primary)

Accounts for approximately 83% of all macular holes. The underlying mechanism is spontaneous vitreomacular traction (VMT) secondary to age-related posterior vitreous detachment (PVD).

Age-related PVD: Liquefaction of the vitreous gel (syneresis) combined with weakened vitreoretinal adhesion leads to incomplete PVD; persistent adhesion at the fovea generates tangential and anteroposterior tractional forces
Müller cell cone disruption: Foveal Müller cells, which form the structural core of the foveola, are particularly vulnerable to traction-induced dehiscence
Centrifugal displacement: Traction-induced centrifugal migration of foveal photoreceptors creates an intraretinal split that progresses to a full-thickness defect

Secondary Causes

High myopia (>6D / axial length >26mm): Posterior staphyloma creates tractional and atrophic forces; myopic macular holes have distinct pathophysiology and often require modified surgical technique
Blunt ocular trauma: Countrecoup force at the fovea (traumatic macular hole); may close spontaneously in younger patients
Epiretinal membrane (ERM): Tangential traction from fibroglial proliferation over the macula
Vitreomacular traction syndrome: Persistent focal vitreoretinal adhesion with documented traction on OCT
Retinal detachment: Macular hole retinal detachment (MHRD), more common in high myopia
Cystoid macular edema (CME): Chronic intraretinal cysts can rupture to the surface forming lamellar or full-thickness holes
Solar retinopathy / photic injury: Direct photochemical damage to foveal photoreceptors
Post-surgical: Following vitreoretinal procedures (e.g., post-RD repair, post-macular buckle)
Choroidal neovascularization (CNV): Subretinal CNV-related disruption in AMD or pathologic myopia
Inflammatory/infectious: Acute retinal necrosis, toxoplasmosis involving the macula (rare)

Vitreous-Foveal Interface Theory (Gass)

The prevailing mechanistic model describes a sequential traction-driven process:

Vitreous syneresis: Age-related liquefaction of the central vitreous creates fluid-filled lacunae (lacunar degeneration); the collagen fibril framework condenses peripherally
Incomplete PVD: As liquefied vitreous dissects between the posterior vitreous cortex and ILM, the cortex separates from most of the posterior pole except at the fovea, where vitreoretinal adhesion is particularly strong
Foveal traction: The remaining vitreoretinal attachment at the fovea generates both anteroposterior (AP) and tangential tractional vectors. AP traction creates a foveal pseudocyst by dehiscing the superficial Müller cell cone from deeper photoreceptors
Foveal pseudocyst formation (Stage 1): The inner foveal layers split, creating an intraretinal hyporeflective cavity on OCT. This appears clinically as a yellow foveal spot (Stage 1a) progressing to a yellow ring (Stage 1b) as the pseudocyst enlarges
Operculum formation (Stage 2→3): Continued traction avulses the foveal cap (operculum) composed of ILM, Müller cell remnants, and occasionally photoreceptors. The operculum may remain attached (Stage 2) or detach freely into the vitreous (Stage 3)
Full-thickness hole (Stage 3–4): The resulting defect extends through all retinal layers. Fluid from the vitreous cavity accumulates beneath the edges, forming a small cuff of subretinal fluid. Retinal tissue at the hole margins undergoes reactive gliosis and centrifugal displacement
Complete PVD (Stage 4): The posterior vitreous fully detaches from the optic disc, removing the tractional stimulus. The hole remains but may occasionally show limited edge reapproximation

Müller Cell Cone Hypothesis

More recent work by Gaudric and colleagues demonstrates that the initial foveal split occurs within the Müller cell cone — a specialised radial glial scaffold at the foveola. These cells are uniquely anchored to the ILM and have minimal lateral support; traction-induced dehiscence at the apex of the cone initiates the pseudocyst before the hole extends to involve photoreceptors and RPE. This explains why Stage 1 holes can close spontaneously if traction is relieved before full-thickness disruption.

Myopic Macular Hole — Distinct Mechanism

In high myopia, posterior staphyloma creates progressive outward traction from scleral expansion. The ILM, rigid relative to the stretched outer retina, exerts tangential stress. Concurrent ERM, foveoschisis (myopic traction maculopathy), and choroidal atrophy all contribute. Myopic macular holes carry a substantially higher risk of progressing to macular hole retinal detachment (MHRD) and generally have a poorer surgical prognosis than idiopathic holes.

Gass Biomicroscopic Classification (1988)

The original staging system based on slit-lamp biomicroscopy; remains clinically relevant for communicating natural history.

Stage	Description	Biomicroscopic Finding	Natural History
Stage 1a Impending	Foveal detachment; pseudocyst forming	Small yellow foveal spot; loss of foveal reflex; Watzke–Allen test negative	~50% spontaneous resolution; ~50% progress to Stage 1b
Stage 1b Impending	Enlarged pseudocyst; operculum still attached	Yellow ring at fovea; roof of pseudocyst intact; Watzke–Allen test negative	~30% spontaneous resolution; ~70% progress to full-thickness hole
Stage 2 Early full-thickness	Small full-thickness hole (<400 μm); vitreous still attached	Round or oval hole with overlying operculum; Watzke–Allen test positive; yellow deposits at base	Most progress to Stage 3 without surgery; VA typically 20/80–20/200
Stage 3 Full-thickness	Full-thickness hole (>400 μm); vitreous still attached; free operculum	Round hole with elevated edges; free operculum overlying hole; cuff of subretinal fluid; yellow deposits; Watzke–Allen positive	Spontaneous closure rare; surgery recommended; VA 20/200–20/400
Stage 4 Full-thickness + PVD	Full-thickness hole with complete PVD	As Stage 3 with visible Weiss ring; PVD confirmed on biomicroscopy or OCT; operculum floating freely in vitreous	Surgery recommended; anatomical and visual outcomes similar to Stage 3

IVTS Group OCT-Based Classification (2013)

The International Vitreomacular Traction Study (IVTS) Group established an OCT-based nomenclature that better predicts surgical outcomes and guides treatment decisions. Macular holes are distinguished from macular pseudoholes (ERM with foveal thinning, no full-thickness defect) and lamellar holes (partial-thickness defect not extending to RPE).

Size Category	Minimum Linear Diameter	Clinical Significance
Small	≤250 μm	Highest spontaneous closure rate; best surgical prognosis; may respond to ocriplasmin (pharmacological vitreolysis)
Medium	250–400 μm	Surgery strongly recommended; ILM peeling improves closure rates; good visual prognosis post-operatively
Large	>400 μm	Surgery essential; inverted ILM flap technique may be preferred; visual recovery more limited but closure still achievable in >85%

The IVTS classification also subdivides holes by tractional status: with VMT (vitreomacular traction present, potentially treatable with ocriplasmin) vs. without VMT (vitreous separated). Causation is further classified as primary (idiopathic) or secondary (identifiable aetiology).

Additional OCT Metrics

Macular Hole Index (MHI): Ratio of hole height to base diameter. MHI >0.5 predicts better post-operative visual acuity
Hole Form Factor (HFF): A more complex metric incorporating hole geometry; HFF >0.9 associated with high closure rates
Tractional component: Presence of epiretinal membrane, persistent VMT, or myopic foveoschisis influences surgical planning
Ellipsoid zone (EZ) integrity: Extent of EZ disruption on OCT correlates with photoreceptor loss and ultimate visual recovery

Non-Modifiable

Age: Incidence rises sharply after age 55; peak incidence in the 7th decade
Female sex: Women constitute approximately 65–70% of idiopathic cases; hormonal changes post-menopause may alter vitreoretinal adhesion properties
Fellow eye status: Approximately 10–15% bilateral incidence; risk in the fellow eye is 7–10% if an attached vitreous is present and rises to 15% with symptomatic VMT in the fellow eye
High myopia: Progressive axial elongation, posterior staphyloma, and myopic foveoschisis substantially elevate risk for both macular hole formation and progression to MHRD

Ocular Risk Factors

Posterior vitreous detachment — particularly anomalous (incomplete) PVD with persistent foveal attachment
Epiretinal membrane — tangential traction component
History of retinal detachment or retinal tear
Prior intraocular surgery (cataract surgery, vitrectomy, scleral buckling)
Blunt ocular trauma
Chronic CME from any cause

Systemic / Other

Corticosteroid use (systemic or topical ophthalmic) — may predispose via posterior subcapsular cataract and altered vitreous dynamics
Race — some evidence suggests lower prevalence in Black populations, possibly due to differences in vitreous structure and PVD timing
Solar/photic exposure (in cases of solar retinopathy)

Biomicroscopic / Fundus Signs

Stage 1: Yellow foveal spot (1a) or ring (1b); loss of foveal reflex; no visible hole
Stage 2–4 full-thickness hole: Round or oval reddish-brown foveal defect with sharply defined edges; appears darker than surrounding retina due to visualisation of the underlying RPE
Elevated hole edges: Slight greyish-white elevation of the surrounding neurosensory retina from subretinal fluid accumulation
Yellow deposits: Small yellowish dots at the base of the hole (lipid-laden macrophages, photoreceptor outer segments, or RPE drusen-like changes)
Operculum: Semi-transparent disc-like structure floating above the hole in the vitreous; present in Stage 3 and 4 (may be visible with careful biomicroscopy using a Volk lens and high magnification)
Weiss ring: Visible annular opacity from the detached vitreous cortex in Stage 4; confirms complete PVD
Subretinal fluid cuff: Small halo of fluid extending 1–2 disc diameters around the hole edges (best appreciated on OCT)
Associated ERM: Fine glistening membrane over the macula in a proportion of cases; may contribute to hole formation or affect surgical approach

Functional / Perimetric Signs

Watzke–Allen test positive: Patient perceives a break or constriction in a thin slit beam directed across the hole; indicates full-thickness defect (negative in pseudohole/lamellar hole)
Laser aiming test positive: 50-μm laser spot projected at hole base not perceived by patient
Amsler grid: Central scotoma, distortion (metamorphopsia), or missing square(s) at fixation
Visual acuity: Stage 2 ~20/80–20/200; Stage 3–4 typically 20/200–20/400; some patients maintain better acuity than expected (eccentric fixation)

Central visual blurring: The most common presenting complaint; characterised by a blurred or hazy central area rather than a complete black spot in early stages
Central scotoma: Absolute or relative central scotoma; may worsen progressively as hole enlarges; reported as a dark or missing area when covering the fellow eye
Metamorphopsia: Distortion of straight lines and shapes; particularly noticeable when reading, driving, or viewing gridded objects; often the earliest symptom reported
Micropsia: Objects appear smaller; caused by displacement of foveal photoreceptors away from the visual axis
Reduced reading ability: Difficulty with fine print; letters may appear to disappear or smear centrally
Photopsia: Flashes of light (photopsia) may precede hole formation during active vitreomacular traction; often unnoticed or attributed to PVD symptoms
Floaters: New floaters may coincide with acute PVD preceding hole formation
Asymptomatic (Stage 1): Early-stage impending holes may be detected incidentally on routine examination before symptoms develop

Clinical note: Patients often minimise symptoms due to compensation by the fellow eye. Unilateral cover testing during history-taking can unmask a significant central scotoma the patient was unaware of. Always assess each eye independently.

Disease-Related Complications

Macular hole retinal detachment (MHRD): Fluid from the vitreous cavity enters the subretinal space through the hole, causing a progressive detachment; risk is highest in highly myopic eyes (incidence ~30% in myopes vs. <1% in idiopathic holes). MHRD is a surgical emergency
Hole enlargement: Untreated full-thickness holes can gradually enlarge over months to years, worsening the central scotoma and reducing surgical prognosis
Photoreceptor loss and RPE atrophy: Chronic hole leads to irreversible RPE and photoreceptor degeneration at the hole base, limiting visual recovery even after successful closure
Bilateral involvement: Fellow-eye hole development in 7–15% of cases; highest risk in the presence of VMT in the fellow eye
Epiretinal membrane development: Reactive gliosis around the hole margin may result in ERM formation that further distorts the macula

Post-Surgical Complications

Cataract formation: The most common post-vitrectomy complication; occurs in virtually all phakic patients within 12–24 months; many surgeons perform combined PPV and phacoemulsification
Persistent or reopened macular hole: Occurs in 5–10% of cases; may require revision surgery with inverted or temporal ILM flap
ERM recurrence: Post-vitrectomy ERM can form and cause macular distortion requiring re-operation
Rhegmatogenous retinal detachment (RRD): Incidence approximately 1–3% post-PPV; related to peripheral breaks during surgery or gas-induced IOP changes
Raised intraocular pressure: From gas tamponade (transient); patients must maintain face-down positioning to avoid optic nerve compression
Endophthalmitis: Rare but vision-threatening; incidence <0.1% with modern technique
Visual field defects: Paracentral scotoma from ILM peeling-induced retinal nerve fibre layer damage; typically small and does not affect functional vision
Photoreceptor displacement (dyschromatopsia, micropsia): May persist post-closure if photoreceptors do not fully re-align to their original positions

Idiopathic macular hole is primarily a local ocular phenomenon with limited direct systemic associations. However, several systemic conditions are relevant to its aetiology, surgical risk stratification, and co-management.

Diabetes Mellitus

Diabetic macular edema (DME) can promote lamellar or full-thickness macular holes via chronic intraretinal cystic degeneration
Tractional macular holes can occur in proliferative diabetic retinopathy (PDR) from fibrovascular membrane contraction
Post-operative hyperglycaemia impairs wound healing and increases infection risk; glycaemic optimisation is recommended pre-operatively

Cardiovascular Disease / Hypertension

Hypertension is associated with accelerated vitreous syneresis and anomalous PVD, potentially increasing macular hole risk
Antiplatelet and anticoagulant medications (aspirin, warfarin, DOACs) require careful peri-operative management; most can be continued through routine vitrectomy but the surgeon must be informed

High Myopia and Connective Tissue Disorders

Marfan syndrome, Stickler syndrome, and Ehlers–Danlos syndrome predispose to high myopia, vitreous degeneration, and macular hole formation; early vitreoretinal surveillance is warranted
Stickler syndrome (type 1 and 2) carries particularly high risk of giant retinal tear, retinal detachment, and macular hole

Corticosteroid Use

Chronic systemic corticosteroids (e.g., for autoimmune disease) accelerate nuclear cataract and may alter vitreous biochemistry
Intravitreal corticosteroid injections (triamcinolone, dexamethasone implant) used for CME treatment occasionally unmask or accelerate macular hole formation in susceptible eyes

Oestrogen / Hormonal Status

The female predominance in idiopathic macular hole may be partly explained by post-menopausal collagen remodelling affecting vitreoretinal adhesion and ILM architecture
Some studies suggest hormone replacement therapy (HRT) may be mildly protective, though evidence is limited and does not justify clinical intervention

History

Onset and duration of central blur and metamorphopsia
Presence of central scotoma (ask patient to cover fellow eye and describe central vision)
History of recent photopsia or floaters (suggests PVD as precipitating event)
Refractive history — degree of myopia, axial length if known
Prior ocular surgery (cataract, vitreoretinal, strabismus)
History of ocular trauma
Systemic medications (anticoagulants, corticosteroids)
Fellow eye status and symptoms

Clinical Examination

1. Best Corrected Visual Acuity (BCVA)

Assess each eye independently; document Snellen/ETDRS
Reduced central VA with relatively preserved peripheral vision is characteristic
A patient with a full-thickness hole maintaining near-normal VA may be using eccentric fixation

2. Amsler Grid Testing

Performed at 33 cm with near correction in place; test each eye separately
Central scotoma (missing squares at fixation) or metamorphopsia (distorted lines) are hallmark findings
Document findings at baseline; useful for patient self-monitoring

3. Slit-Lamp Biomicroscopy with Non-Contact Lens

Non-dilated fundus imaging and OCT are the primary assessment tools in the optometric setting (see Singapore Scope Note under Management)
If dilated examination is performed by a medical practitioner: assess with 90D or 78D lens; look for foveal defect, operculum, cuff of subretinal fluid, ERM, and vitreous status
Watzke–Allen test: A narrow slit beam projected across the hole; a full-thickness hole causes the patient to perceive a thinning or break in the beam; negative in pseudohole or lamellar hole

Imaging and Ancillary Tests

Optical Coherence Tomography (OCT) — Primary Diagnostic Tool

OCT is the gold standard for macular hole diagnosis, staging, sizing, and surgical planning. It can be performed non-dilated in the optometric setting.

Full-thickness hole: Discontinuity of all retinal layers from ILM to RPE at the fovea; hyporeflective gap with elevated edges; subretinal fluid cuff; possible operculum in vitreous
Lamellar hole: Partial-thickness defect; inner foveal concavity with breach of inner retinal layers but intact photoreceptor layer and RPE — distinguished from full-thickness hole on OCT
Pseudohole: ERM with steep foveal contour and apparent hole appearance on fundus exam; OCT confirms intact retinal layers throughout
Minimum linear diameter (MLD): Measured at the narrowest point of the hole; determines IVTS size category (small/medium/large)
Base diameter, hole height, MHI, HFF: Prognostic metrics quantified on OCT for surgical planning
Ellipsoid zone (EZ) disruption: Extent of outer retinal layer disruption; predicts potential for visual recovery post-operatively
Vitreomacular traction (VMT): Perifoveal vitreous attachment visible on OCT; presence informs eligibility for pharmacological vitreolysis
En face OCT: Provides circular or irregular shape assessment of the hole; useful pre-operatively

Fundus Photography / Colour Fundus

Documents hole size, surrounding RPE changes, ERM, and any subretinal fluid clinically
Baseline documentation for monitoring and medicolegal purposes
Infrared reflectance imaging can highlight ERM and ILM traction patterns

Optical Coherence Tomography Angiography (OCTA)

Not routinely required for diagnosis, but useful to evaluate for secondary causes (CNV in AMD or myopia) and to assess foveal avascular zone (FAZ) changes
May show enlarged FAZ and disrupted superficial/deep capillary plexus architecture at hole margins

Fluorescein Angiography (FA)

Not routinely indicated for idiopathic macular holes; OCT has largely replaced FA in this context
May be used to rule out secondary CNV, vascular occlusion, or inflammatory aetiology
Classic finding: hyperfluorescence (window defect) at the hole site corresponding to RPE exposure

Visual Field Testing (Central 10-2 or Amsler)

Central 10-2 automated perimetry or frequency doubling technology (FDT) for the central field
Documents central scotoma; useful for medicolegal documentation and monitoring
Not required routinely if OCT is diagnostic but supports functional impact assessment

Singapore Optometry Scope Note: Optometrists in Singapore do not perform dilated fundus examination. Assessment of the macula is conducted using non-dilated OCT, fundus photography, and ancillary tests available within the optometric scope. Any patient presenting with central scotoma, metamorphopsia, or reduced visual acuity with macular hole suspected or confirmed on OCT should be referred promptly to ophthalmology (vitreoretinal specialist). The optometrist's role is accurate detection, timely referral, patient counselling regarding face-down positioning compliance, and post-operative monitoring of visual acuity and Amsler grid changes using non-dilated imaging modalities.

Observation (Stage 1 / Impending Holes)

Stage 1a and 1b holes may be observed initially; ~30–50% undergo spontaneous resolution as the vitreous detaches and relieves foveal traction
Observation period typically 3–4 months with serial OCT monitoring
Instruct patient to monitor with Amsler grid daily; report worsening blur or scotoma promptly
Immediate surgical evaluation if progression to full-thickness hole is detected on OCT

Pharmacological Vitreolysis — Ocriplasmin (Jetrea®)

Recombinant truncated plasmin injected intravitreally; cleaves fibronectin and laminin at the vitreoretinal interface to induce enzymatic PVD
Indications: Small full-thickness macular hole (≤400 μm) with confirmed VMT on OCT; most effective in holes ≤250 μm with concurrent VMT
Closure rate: ~40% in small holes with VMT (vs. ~10% placebo); declines to ~25% for holes up to 400 μm
Single intravitreal injection 0.125 mg/0.1 mL; no face-down positioning required
Side effects: transient visual disturbance, dyschromatopsia (yellow–green tint, typically resolves within weeks), transient EZ disruption on OCT (may initially worsen OCT appearance), photopsia
Not effective for large holes (>400 μm), holes without VMT, or myopic holes; surgery remains the standard for these cases

Pars Plana Vitrectomy (PPV) — Definitive Surgical Treatment

PPV with ILM peeling and gas tamponade is the current standard of care for full-thickness macular holes (Stage 2–4). Anatomical closure is achieved in >90% of cases with modern technique.

Core Surgical Steps

Vitrectomy: 23–27 gauge PPV to remove the vitreous gel; induction of PVD if not already present using active suction over the optic disc
ILM peeling: Internal limiting membrane peeling (typically stained with indocyanine green (ICG), triamcinolone, or Brilliant Blue G (BBG)) removes the ILM over 1–2 disc diameters around the hole; eliminates tangential traction and stimulates glial proliferation to seal the hole
Gas tamponade: Air-fluid exchange followed by injection of a long-acting gas (SF6 20% or C3F8 14%); the gas bubble provides sustained surface tension to appose hole edges over 1–3 weeks
Face-down positioning: Patient must maintain face-down (prone) position for 1–7 days post-operatively (duration varies by surgeon preference and hole size) to keep the gas bubble over the fovea

Surgical Variants for Large or Recalcitrant Holes

Inverted ILM flap technique (Michalewska): Rather than removing the ILM entirely, it is inverted and draped over the hole; provides a scaffold for glial cell migration; recommended for large holes (>400 μm) and myopic holes; closure rates >90% for large holes
Free ILM flap: ILM from the fellow eye or same eye is used to plug the hole; emerging technique for previously failed surgeries
Lens-sparing PPV: In young patients or those with mild lens opacity to preserve accommodation
Combined phacoemulsification + PPV: Performed simultaneously in phakic patients >55 years to avoid sequential surgery and improve visualisation
Silicone oil tamponade: Used in myopic MHRD or cases where C3F8 gas is contraindicated (e.g., planned air travel); requires a second procedure for oil removal

Post-Operative Monitoring

OCT at 4–6 weeks post-operatively to confirm anatomical closure; serial OCT at 3, 6, and 12 months
BCVA typically improves over 3–12 months; maximum visual recovery may not occur until 12–24 months post-closure
Patients must avoid flying or high altitude travel while gas tamponade is present (gas expansion at altitude can cause acute angle-closure glaucoma)
Monitor for cataract progression post-vitrectomy; plan cataract surgery when clinically appropriate
Amsler grid self-monitoring at home post-operatively; report any new central distortion

Refer to Ophthalmology (Vitreoretinal) for:

Urgent (within days):

Suspected or confirmed macular hole retinal detachment (MHRD)
Acute onset central scotoma with rapid visual deterioration
Full-thickness hole in a highly myopic eye (high MHRD risk)

Prompt (within 1–2 weeks):

Any confirmed full-thickness macular hole (Stage 2–4) on OCT
Stage 1 hole failing to resolve after 3 months of observation
Significant metamorphopsia or VA loss attributable to macular hole
Fellow eye with active VMT or impending hole

Anatomical Outcome

Stage 1 (observation): ~30–50% spontaneous resolution; poor prognostic sign if VMT persists beyond 4 months
Stage 2 (small holes): Surgical closure rates >95% with PPV + ILM peel
Stage 3–4 (medium/large holes): Closure rates 90–95% for standard technique; >90% with inverted ILM flap for large holes
Myopic holes: Lower closure rates (~70–80%); inverted ILM flap or free flap improves outcomes; high risk of progression to MHRD if repair delayed
Chronic holes (>1 year duration): Reduced closure rates and poorer visual prognosis; RPE and photoreceptor atrophy at the hole base limits recovery

Visual Outcome

Excellent (≥20/40): Approximately 40–50% of successfully closed holes; more common in small holes, shorter duration, and intact EZ on pre-operative OCT
Good (20/50–20/100): Approximately 30–40% of cases; meaningful improvement in reading and daily function
Moderate (20/100–20/200): Residual metamorphopsia and scotoma may persist despite anatomical closure if photoreceptors do not fully realign
Poor (<20/200): Large holes with prolonged duration, chronic RPE atrophy, or failed surgery; low vision rehabilitation may be needed

Favourable Prognostic Factors

Short duration of symptoms (<6 months)
Small hole diameter (<250–400 μm)
High MHI (>0.5) and HFF (>0.9)
Intact or minimally disrupted ellipsoid zone on pre-operative OCT
Younger patient age (<60 years)
Absence of high myopia
No prior failed surgery

Persistent Symptoms Post-Closure

Even after successful anatomical closure (confirmed on OCT), patients frequently report residual metamorphopsia, micropsia, or dyschromatopsia for months. This reflects photoreceptor misalignment and outer segment recovery rather than surgical failure. The EZ continuity on OCT is the best predictor of final visual function; full reconstitution may take 12–24 months and is often incomplete in large or chronic holes.

Condition	Key Distinguishing Features	OCT Differentiation
Macular Pseudohole	Associated ERM creating apparent hole; visual acuity often better preserved; Watzke–Allen negative; no central scotoma	ERM visible; foveal contour steep but all retinal layers intact through fovea; no gap to RPE
Lamellar Macular Hole	Partial-thickness defect; mild metamorphopsia; VA often 20/40–20/80; may be stable over years	Irregular foveal contour with breach of inner retinal layers but intact photoreceptors and RPE; ERM often present
Cystoid Macular Edema (CME)	Post-surgical, diabetic, or inflammatory; may mimic hole clinically; responds to anti-inflammatory treatment	Intraretinal cystic spaces; retinal thickening; no full-thickness gap; fluid signal rather than empty space
Central Serous Retinopathy (CSR)	Younger males; subretinal fluid; stress/steroid association; metamorphopsia and micropsia; foveal detachment	Subretinal fluid dome; neurosensory detachment; intact retinal layers; no full-thickness gap; RPE changes/detachments
Age-Related Macular Degeneration (AMD)	Drusen, RPE changes, CNV possible; visual loss often gradual; Amsler distortion from CNV; may be bilateral	Drusen, RPE atrophy, CNV; may show subretinal/intraretinal fluid but no full-thickness foveal gap (unless secondary hole)
Epiretinal Membrane (ERM)	Metamorphopsia and VA loss without central scotoma; glistening surface sheen on fundus exam; may coexist with macular hole	Hyperreflective membrane on ILM surface; macular distortion and thickening; intact retinal layers; no full-thickness break
Vitreomacular Traction (VMT) without Hole	Metamorphopsia and VA loss from traction; no complete break; may be treated with ocriplasmin or observation	Vitreous attachment visible at fovea; intraretinal distortion; possible foveal cyst; intact retinal layers (pre-hole state)
Solar / Photic Retinopathy	History of direct solar viewing (eclipse, welding); acute onset after exposure; may appear as small foveal lesion	Small hyperreflective or hyporeflective foveal lesion; may have outer retinal disruption without full-thickness gap; often partial-thickness
Myopic Foveoschisis	High myopia; splitting of retinal layers without full-thickness break; may precede myopic macular hole	Intraretinal splitting between outer and inner layers; posterior staphyloma on B-scan; ILM detachment possible; no full-thickness gap unless progresses to hole

Do not dismiss early-stage macular holes as benign. Stage 1a and 1b holes have ~50–70% progression risk to full-thickness if VMT persists. Urgent OCT and ophthalmology referral at the first sign of a foveal lesion with metamorphopsia prevents avoidable visual loss. The window for pharmacological treatment (ocriplasmin) is narrow — once the hole exceeds 400 μm, this option is lost.

OCT is more sensitive than clinical examination for macular holes. The Watzke–Allen test and other bedside tests have limited sensitivity for early and small holes. A high-quality OCT through the fovea is essential whenever central metamorphopsia or scotoma is reported. Do not rely on fundus appearance alone — Stage 1 holes are often invisible on funduscopy.

Always test the fellow eye. With 10–15% bilateral incidence and a subset showing VMT in the fellow eye, the unaffected eye must be assessed at every visit. Undetected Stage 1 disease in the fellow eye is a common oversight. Document fellow-eye OCT at baseline and at least annually in confirmed unilateral cases.

Distinguish full-thickness hole from pseudohole before referral. ERM-associated pseudoholes and lamellar holes have a very different natural history and management pathway. Misclassification leads to unnecessary urgent referrals or, conversely, delayed intervention. The Watzke–Allen test and OCT are complementary — use both when available and document clearly in the referral letter.

High myopia + macular hole = urgent referral. Macular hole retinal detachment (MHRD) can develop rapidly in highly myopic eyes and is rarely reversible without prompt surgical repair. Any full-thickness hole in a patient with >6D myopia or posterior staphyloma should be referred urgently, even if asymptomatic for MHRD, as the risk of progression is substantially higher than in emmetropic eyes.

Counsel patients on face-down positioning compliance before surgery. Post-operative outcomes are significantly influenced by adherence to face-down positioning, which keeps the gas tamponade over the fovea. Patients with physical limitations (musculoskeletal disorders, obesity, dementia) may struggle with compliance; early discussion allows the surgical team to plan modified positioning protocols or consider longer-acting gas alternatives.

Singapore Optometry Scope Note — Using OCT for macular hole triage. Non-dilated spectral-domain OCT is within scope for Singapore optometrists and is the single most important tool for detecting and characterising macular holes. Document the minimum linear diameter (MLD), the presence or absence of VMT, EZ integrity, and subretinal fluid cuff at every OCT assessment. A clearly structured OCT report with these parameters significantly enhances the quality of the vitreoretinal referral and helps the receiving ophthalmologist prioritise urgency.

Gass JD. Idiopathic senile macular hole. Its early stages and pathogenesis. Arch Ophthalmol. 1988;106(5):629–639.
Duker JS, Kaiser PK, Binder S, et al.; International Vitreomacular Traction Study Group. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120(12):2611–2619.
Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes: results of a pilot study. Arch Ophthalmol. 1991;109(5):654–659.
Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc. 2005;103:537–567.
Stalmans P, Benz MS, Gandorfer A, et al.; MIVI-TRUST Study Group. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012;367(7):606–615.
Michalewska Z, Michalewski J, Adelman RA, Nawrocki J. Inverted internal limiting membrane flap technique for large macular holes. Ophthalmology. 2010;117(10):2018–2025.
Steel DH, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond). 2013;27(Suppl 1):S1–21.
Forsaa VA, Lindtjørn B, Kvaløy JT, Frøystein T, Krohn J. Epidemiology and morphology of full-thickness macular holes. Acta Ophthalmol. 2018;96(4):397–404.
Ip MS, Baker BJ, Duker JS, et al. Anatomical outcomes of surgery for idiopathic macular hole as determined by optical coherence tomography. Arch Ophthalmol. 2002;120(1):29–35.
Tadayoni R, Gaudric A, Haouchine B, Massin P. Relationship between macular hole size and the potential benefit of internal limiting membrane peeling. Br J Ophthalmol. 2006;90(10):1239–1241.
Kumagai K, Ogino N, Furukawa M, Larson E. Surgical outcomes for full-thickness macular holes with high myopia. Am J Ophthalmol. 2007;144(2):229–235.
Ezra E, Gregor ZJ; Moorfields Macular Hole Study Group Report. Surgery for idiopathic full-thickness macular hole: two- to eight-year follow-up of a pilot randomized controlled surgical trial. Arch Ophthalmol. 2004;122(2):224–236.
Chew EY, Sperduto RD, Hiller R, et al. Clinical course of macular holes: the Eye Disease Case-Control Study. Arch Ophthalmol. 1999;117(2):242–246.
Thompson JT, Sjaarda RN, Lansing MB. The results of vitreous surgery for chronic macular holes. Retina. 1997;17(6):493–499.
Eckardt C, Eckert T, Eckardt U, Porkert U, Gesser C. Macular hole surgery with air tamponade and optical coherence tomography-based duration of face-down positioning. Retina. 2008;28(8):1087–1096.
Gaudric A, Haouchine B, Massin P, Paques M, Blain P, Erginay A. Macular hole formation: new data provided by optical coherence tomography. Arch Ophthalmol. 1999;117(6):744–751.
Takahashi A, Nagaoka T, Ishiko S, Kameyama D, Yoshida A. Foveal anatomical changes in a progressing stage 1 macular hole documented by spectral-domain optical coherence tomography. Ophthalmology. 2010;117(4):806–810.
Alkabes M, Pichi F, Nucci P, et al. Anatomical and visual outcomes in high myopic macular hole (HM-MH) without retinal detachment: a review. Graefes Arch Clin Exp Ophthalmol. 2014;252(2):191–199.

Clinical Illustration